Spectral AI (MDAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
The annual meeting is scheduled for May 29, 2026, both in-person and virtually, to maximize shareholder participation and communication.
Proxy materials are distributed via internet under SEC's notice and access rules, with paper copies available upon request.
Shareholders of record as of April 1, 2026, are entitled to vote on all proposals.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting or until successors are elected.
Ratification of Forvis Mazars, LLP as the independent registered public accounting firm for fiscal 2026.
Authorization for the reservation and issuance of up to 8,000,000 shares of common stock to Hudson Bay Master Fund Ltd. under a Securities Purchase Agreement, in compliance with Nasdaq Rule 5635(d).
Any other business that may properly come before the meeting.
Board of directors and corporate governance
The board consists of five directors, with a mix of executive and independent members, and all attended at least 75% of meetings in 2025.
Standing committees include Audit, Compensation, Nominating and Corporate Governance, Science and Technology, and Executive Committees, each with defined charters.
The Office of the Chairman was dissolved in February 2026, with Vincent Capone appointed CEO and Dr. DiMaio remaining as Chairman.
The board has adopted a Code of Conduct, Corporate Governance Guidelines, and an Insider Trading Policy.
Latest events from Spectral AI
- FDA clearance enables 2026 commercial launch; net loss narrows, cash at $14M, revenue still government-based.MDAI
Q2 2026 - Q1 2026 revenue fell to $4.0M, net loss was $3.4M, and BARDA funding advanced DeepView.MDAI
Q1 2026 - Director elections, auditor ratification, and share issuance to Hudson Bay Master Fund Ltd. on agenda.MDAI
Proxy filing - Shareholders will vote on director elections, auditor ratification, and a significant share issuance.MDAI
Proxy filing - 2025 net loss narrowed, cash rose to $15.4M, and 2026 revenue is forecast at $18.5M.MDAI
Q4 2025 - Q3 revenue up 138% to $8.2M, margins improved, and FDA submission and spin-off plans advance.MDAI
Q3 2024 - AI-driven wound care system nears FDA submission, with UK pilots and strong funding support.MDAI
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Q2 revenue up 76% year-over-year; UK commercialization and FDA submission on track.MDAI
Q2 2024 - Record R&D revenue and clinical validation position DeepView for 2025 FDA submission.MDAI
Q4 2024